Change - Announcement of Appointment::Appointment of Chief Executive Officer

Issuer & Securities

Issuer/ Manager
MANULIFE US REAL ESTATE MANAGEMENT PTE. LTD.
Securities
MANULIFE US REIT - SG1CI1000004 - BTOU
Stapled Security
No

Announcement Details

Announcement Title
Change - Announcement of Appointment
Date &Time of Broadcast
04-May-2022 18:01:58
Status
New
Announcement Sub Title
Appointment of Chief Executive Officer
Announcement Reference
SG220504OTHR5RTL
Submitted By (Co./ Ind. Name)
Tan Ling Ling
Designation
Company Secretary
Description (Please provide a detailed description of the event in the box below)
Appointment of William David Gantt III (Tripp Gantt) as Chief Executive Officer

Additional Details

Date Of Appointment
06/05/2022
Name Of Person
William David Gantt III (Tripp Gantt)
Age
52
Country Of Principal Residence
Singapore
The Board's comments on this appointment (including rationale, selection criteria, and the search and nomination process)
The Nominating and Remuneration Committee and Board, having considered Mr Gantt's professional qualifications and past working experience, is satisfied that Mr Gantt has the requisite knowledge and experience to assume the duties and responsibilities as the Chief Executive Officer of the Company.

Mr Gantt has over 23 years of real estate experience, including 16 years overseeing real estate operating companies on behalf of the Washington State Investment Board, a US pension fund with an AUM of approximately $25 billion in real estate.
Whether appointment is executive, and if so, the area of responsibility
The appointment is executive. Mr Gantt will work with the Board to determine the strategy for Manulife US REIT (MUST) as well as with other members of the management team to execute MUST's investment strategy.

Mr Gantt will also be responsible for the overall day-to-day management and operations of MUST, working with the Manager's investment, asset management, financial and legal and compliance personnel in meeting the strategic, investment and operational objectives of MUST.
Job Title (e.g. Lead ID, AC Chairman, AC Member etc.)
Chief Executive Officer
Professional qualifications
Nil
Any relationship (including immediate family relationships) with any existing director, existing executive officer, the issuer and/ or substantial shareholder of the listed issuer or any of its principal subsidiaries
Nil
Conflict of interests (including any competing business)
Nil
Working experience and occupation(s) during the past 10 years
February 2022 to present
- Deputy Chief Executive Officer, Manulife US Real Estate Management Pte. Ltd.

June 2005 to January 2022
- Assistant Senior Investment Officer, Washington State Investment Board
Undertaking submitted to the listed issuer in the form of Appendix 7.7 (Listing Rule 704(7)) Or Appendix 7H (Catalist Rule 704(6))
Yes
Shareholding interest in the listed issuer and its subsidiaries?
No
# These fields are not applicable for announcements of appointments pursuant to Listing Rule 704 (9) or Catalist Rule 704 (8).
Past (for the last 5 years)
Everview Capital Partners -Non-Executive Director
Crane Capital Partners, LLC -Advisory Board
Evergreen Real Estate Partners, LLC - Advisory Board
Gateway China Real Estate Fund III, LP - Advisory Committee
Gateway China Real Estate Fund V, LP - Advisory Committee
Gaw NP Vietnam Fund I, LP - Advisory Committee
Indochina Land Holdings 3, LP - Advisory Committee
Century Bridge China Real Estate Fund, LP - Investor Advisory Committee
Century Bridge China Real Estate Fund II, LP - Investor Advisory Committee
Warburg Pincus Real Estate I, LP - Advisory Committee, Valuation Committee
Union Square, LLC - Executive Managing Board
Present
None
(a) Whether at any time during the last 10 years, an application or a petition under any bankruptcy law of any jurisdiction was filed against him or against a partnership of which he was a partner at the time when he was a partner or at any time within 2 years from the date he ceased to be a partner?
No
(b) Whether at any time during the last 10 years, an application or a petition under any law of any jurisdiction was filed against an entity (not being a partnership) of which he was a director or an equivalent person or a key executive, at the time when he was a director or an equivalent person or a key executive of that entity or at any time within 2 years from the date he ceased to be a director or an equivalent person or a key executive of that entity, for the winding up or dissolution of that entity or, where that entity is the trustee of a business trust, that business trust, on the ground of insolvency?
No
(c) Whether there is any unsatisfied judgment against him?
No
(d) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving fraud or dishonesty which is punishable with imprisonment, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such purpose?
No
(e) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such breach?
No
(f) Whether at any time during the last 10 years, judgment has been entered against him in any civil proceedings in Singapore or elsewhere involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or a finding of fraud, misrepresentation or dishonesty on his part, or he has been the subject of any civil proceedings (including any pending civil proceedings of which he is aware) involving an allegation of fraud, misrepresentation or dishonesty on his part?
No
(g) Whether he has ever been convicted in Singapore or elsewhere of any offence in connection with the formation or management of any entity or business trust?
No
(h) Whether he has ever been disqualified from acting as a director or an equivalent person of any entity (including the trustee of a business trust), or from taking part directly or indirectly in the management of any entity or business trust?
No
(i) Whether he has ever been the subject of any order, judgment or ruling of any court, tribunal or governmental body, permanently or temporarily enjoining him from engaging in any type of business practice or activity?
No
(j) Whether he has ever, to his knowledge, been concerned with the management or conduct, in Singapore or elsewhere, of the affairs of :-
(i) any corporation which has been investigated for a breach of any law or regulatory requirement governing corporations in Singapore or elsewhere; or
No
(ii) any entity (not being a corporation) which has been investigated for a breach of any law or regulatory requirement governing such entities in Singapore or elsewhere; or
No
(iii) any business trust which has been investigated for a breach of any law or regulatory requirement governing business trusts in Singapore or elsewhere; or
No
(iv) any entity or business trust which has been investigated for a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, in connection with any matter occurring or arising during that period when he was so concerned with the entity or business trust?
No
(k) Whether he has been the subject of any current or past investigation or disciplinary proceedings, or has been reprimanded or issued any warning, by the Monetary Authority of Singapore or any other regulatory authority, exchange, professional body or government agency, whether in Singapore or elsewhere?
No
Any prior experience as a director of an issuer listed on the Exchange?
No
If no, please state if the director has attended or will be attending training on the roles and responsibilities of a director of a listed issuer as prescribed by the Exchange
N.A.
Please provide details of relevant experience and the nominating committee's reasons for not requiring the director to undergo training as prescribed by the Exchange (if applicable)
N.A.